DNA Biomed Solns (DNA) — Cash Flow Quality Index
Latest as of June 2023:
-0.21x
DNA Biomed Solns (DNA) has a Cash Flow Quality Index of -0.21x as of June 2023. Operating cash flow of ILA-265.00K is below net income of ILA1.27 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore DNA operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
-0.21x
Operating CF / Net Income
Operating Cash Flow
ILA-265.00K
ILA
Net Income
ILA1.27 Million
ILA
Data as of
Jun 2023
Most recent filing
DNA Biomed Solns Cash Flow Quality Index (2017–2024)
Historical Cash Flow Quality Index for DNA Biomed Solns across 3 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see DNA operating cash flow.
Annual Cash Flow Quality Index for DNA Biomed Solns (2017–2024)
Year-by-year earnings quality comparison for DNA Biomed Solns.
| Year | Quality Index | Operating CF (ILA) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 0.07x | ILA1.61 Million | ILA22.10 Million | ▲ +157.4% |
| 2021 | -0.13x | ILA-2.33 Million | ILA18.37 Million | ▼ -881.3% |
| 2017 | -0.01x | ILA-1.91 Million | ILA147.36 Million | — |
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.